Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2020, Vol. 25 ›› Issue (4): 421-425.doi: 10.12092/j.issn.1009-2501.2020.04.011

Previous Articles     Next Articles

Protection of subjects' legal rights, welfare and safety in clinical trials of COVID-19

ZHANG Zhengfu, LI Meng, WANG Jianan   

  1. Center for Food and Drug Inspection of NMPA, Beijing 100044, China
  • Received:2020-03-10 Revised:2020-03-25 Online:2020-04-26 Published:2020-05-12

Abstract: Since December 2019, COVID-19 has been found in Wuhan, Hubei Province of China, which has spread in many countries and regions around the world. A large number of clinical trials have been launched in China aiming to find safe and effective drugs and treatments.The protection of subjects' legal rights, welfare and safety should be superior to the consideration of scientific and social benefits. Therefore, all parties involved in clinical trials should take corresponding measures to protect subjects' legal rights, welfare and safety. This paper discussed about the protection of subjects' legal rights, welfare and safety in clinical trials of COVID-19 from all aspects of the clinical trials, aiming to provide reference for all parties involved in clinical trials and basic ideas for the protection of subjects' legal rights, welfare and safety in clinical trials of emergencies.

Key words: COVID-19, clinical trials, protection of subjects' legal rights

CLC Number: